Objective Capital Management LLC boosted its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 20.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,195 shares of the biopharmaceutical company’s stock after purchasing an additional 1,061 shares during the period. Objective Capital Management LLC’s holdings in Pfizer were worth $317,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in PFE. Moneta Group Investment Advisors LLC grew its position in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after purchasing an additional 160,963,976 shares in the last quarter. Norges Bank bought a new position in shares of Pfizer in the 4th quarter valued at about $3,150,472,000. Morgan Stanley grew its position in shares of Pfizer by 10.3% in the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after acquiring an additional 7,419,929 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 13.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock valued at $3,097,341,000 after acquiring an additional 6,972,650 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Pfizer in the 1st quarter valued at about $311,238,000. Institutional investors own 67.62% of the company’s stock.
Analyst Ratings Changes
PFE has been the subject of a number of analyst reports. Bank of America decreased their price objective on shares of Pfizer from $50.00 to $45.00 and set a “neutral” rating for the company in a research report on Friday, April 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Pfizer in a research report on Wednesday, May 17th. JPMorgan Chase & Co. set a $45.00 price objective on shares of Pfizer in a research report on Monday, February 27th. Jefferies Financial Group started coverage on shares of Pfizer in a report on Monday, March 6th. They set a “hold” rating and a $43.00 target price for the company. Finally, Barclays reduced their target price on shares of Pfizer from $43.00 to $40.00 in a report on Wednesday, May 3rd. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $47.33.
Insider Activity
Pfizer Price Performance
Shares of NYSE:PFE opened at $40.08 on Friday. The firm has a 50 day moving average of $38.96 and a 200-day moving average of $43.12. The stock has a market capitalization of $226.26 billion, a PE ratio of 7.89, a PEG ratio of 1.32 and a beta of 0.64. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.31. Pfizer Inc. has a 12 month low of $36.17 and a 12 month high of $54.93.
Pfizer (NYSE:PFE – Get Rating) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.00 by $0.23. The company had revenue of $18.28 billion during the quarter, compared to analysts’ expectations of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The business’s revenue for the quarter was down 28.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.62 EPS. On average, equities research analysts predict that Pfizer Inc. will post 3.35 EPS for the current fiscal year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, June 9th. Stockholders of record on Friday, May 12th were given a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 4.09%. The ex-dividend date was Thursday, May 11th. Pfizer’s payout ratio is presently 32.28%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Micron Building Goodwill In Asia, Near $2 Billion Investment
- Is Twilio On The Verge Of A Comeback?
- Broadcom: All-Time Highs But Still Good Value
- Leverage AI And Build A Fortress Portfolio With Adobe
- 2 Small-Caps With Large-Cap Potential
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
